$AIMMay 27, 2026, 12:47 PMAI processed
AIM says Ampligen gave 100% survival in USAMRIID Ebola mouse study; investor video June 4
AI Summary
AIM ImmunoTech will publish an on‐demand investor presentation on June 4 highlighting a previously published USAMRIID BSL‐4 preclinical study where Ampligen (rintatolimod) produced 100% survival with early dosing in a lethal Ebola mouse model. The company frames this as relevant amid a WHO-declared Bundibugyo outbreak and notes Ampligen's TLR3-based mechanism and existing orphan drug designations, but the result is preclinical and no new human data or clinical trial starts were announced.
Positives
- USAMRIID BSL‑4 mouse study reported 100% survival with early Ampligen treatment vs 100% mortality in untreated controls
- Effective protective dose in mice was reported at 6 mg/kg, a dose AIM says is generally well tolerated in humans
- Ampligen already holds Orphan Drug designation for Ebola from both FDA and EMA
Negatives
- Results are preclinical (mouse) and do not establish human efficacy; human trials are required
- No new clinical data, trial initiations, regulatory submissions, or government contracts were announced
- Company is repackaging previously published results into an investor presentation rather than reporting fresh readouts